about
Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice.Retrospective study of clinical and lesions'characteristics of patients undergoing surgical treatment for their Pulmonary Tuberculosis in GeorgiaThe Progress of Therapeutic Vaccination with Regard to TuberculosisThe production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine productionFoamy macrophages and the progression of the human tuberculosis granulomaProphylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosisGranuloma encapsulation is a key factor for containing tuberculosis infection in minipigsOral Administration of Heat-Killed Mycobacterium manresensis Delays Progression toward Active Tuberculosis in C3HeB/FeJ Mice.The scavenger protein apoptosis inhibitor of macrophages (AIM) potentiates the antimicrobial response against Mycobacterium tuberculosis by enhancing autophagy.Development of the food supplement Nyaditum resae as a new tool to reduce the risk of tuberculosis development.Pilot, double-blind, randomized, placebo-controlled clinical trial of the supplement food Nyaditum resae® in adults with or without latent TB infection: Safety and immunogenicityFoamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistenceDraft Genome Sequences of Mycobacterium setense Type Strain DSM-45070 and the Nonpathogenic Strain Manresensis, Isolated from the Bank of the Cardener River in Manresa, Catalonia, SpainWhat We Have Learned and What We Have Missed in Tuberculosis Pathophysiology for a New Vaccine Design: Searching for the "Pink Swan".To achieve an earlier IFN-γ response is not sufficient to control Mycobacterium tuberculosis infection in mice.Low dose aerosol fitness at the innate phase of murine infection better predicts virulence amongst clinical strains of Mycobacterium tuberculosisNewborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routesSafety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection.Multiple consecutive infections might explain the lack of protection by BCG.Experimental model of tuberculosis in the domestic goat after endobronchial infection with Mycobacterium capraeWidespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosisRUTI: a new chance to shorten the treatment of latent tuberculosis infection.Individual-Based Modeling of Tuberculosis in a User-Friendly Interface: Understanding the Epidemiological Role of Population Heterogeneity in a City.Local Inflammation, Dissemination and Coalescence of Lesions Are Key for the Progression toward Active Tuberculosis: The Bubble ModelInduction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis.Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection.Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse.A dynamic reinfection hypothesis of latent tuberculosis infection.Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif.Tuberculin immunotherapy: its history and lessons to be learned.Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease.The secret trumps, impelling the pathogenicity of tubercle bacilli.A spotlight on liquefaction: evidence from clinical settings and experimental models in tuberculosis.Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.The lack of a big picture in tuberculosis: the clinical point of view, the problems of experimental modeling and immunomodulation. The factors we should consider when designing novel treatment strategies.Therapeutic vaccines for tuberculosis--a systematic review.The key role of exudative lesions and their encapsulation: lessons learned from the pathology of human pulmonary tuberculosis.Towards host-directed therapies for tuberculosis.The Small Breathing Amplitude at the Upper Lobes Favors the Attraction of Polymorphonuclear Neutrophils to Mycobacterium tuberculosis Lesions and Helps to Understand the Evolution toward Active Disease in An Individual-Based Model.Experimental animal modelling for TB vaccine development.
P50
Q21136107-477BB4E1-DBF5-47AA-AF9B-4734ECE7C373Q28070088-BD542BA2-CFA5-4615-9F06-BD92330C0F10Q28072271-21CD51CD-52D0-4F21-9839-EA3B113D1D69Q28237723-25FA3146-4954-4F7F-8492-9651A42B2D5CQ28255669-7EA259B6-0F5E-4971-8C63-A8D047AC2C19Q28744312-39E467F4-9956-47D2-A6D6-233915D7D250Q28748169-D74CB6C6-2EA8-4CE8-8C37-423EC5EF440FQ31037455-1C598BCF-5ECE-41B1-A080-48C61DAA805AQ31143734-B5D25EC6-6A59-4004-99EC-45A77B05A601Q31152311-C90D3B92-4F96-4B18-8299-CB92742B2F46Q31160709-0F51DD44-4DC6-4286-9D86-0623E22B23BFQ33383817-23974F99-EE95-4909-9C79-D967D2EB0407Q33457148-8148945C-64B3-45A9-858C-62F77B7EE4DFQ33679240-8AFC0915-667E-4B5F-BF07-028048750ACAQ33800857-21781AAD-6B96-4A22-B18D-C4DCD1D1B80AQ34123530-DA609296-A792-4E95-9EDB-B4A9CE9105E0Q34983688-255B5BBB-1B9C-4111-BCBC-A969538B6E6EQ35107731-BD58FDA4-7B72-4BC0-A3B1-C6A32E643635Q35150684-8254B299-5D91-4720-BFC9-402657C07860Q35530263-1E51EED1-45BC-4833-BF97-D4C94CBFAB9CQ36044574-979D7E02-F1E3-4279-98F4-A29C62A8CCC8Q36424616-D4240EE7-057C-4E6C-B9E1-A8E014E9E82EQ36453072-133595AB-222A-4DCA-BF93-750FD4D05EAEQ36529912-2CAA861E-41DC-48A0-94DE-5D3EDBF83673Q36844900-D646FDEC-AFB7-4CAD-A3E6-16166809B911Q36853424-FE317ED7-D043-4B32-9BED-A0B29D2F1EF9Q36974318-9F4BF4F6-6218-4208-9D4D-A0D6281DAB2EQ37421313-4A9EB094-6D24-4A11-A025-E1E423D030D7Q37584635-67E520EA-644E-4470-AC6F-C3E600A7C149Q37628881-50B64BFD-3B68-4B9B-B86C-F326F626901BQ37668167-40A7DB05-820C-4616-97C2-D91BD5105B57Q37855144-0EC456C1-6E6C-4877-AC87-07F91EDFC4A4Q37857711-E7E92380-9857-487C-AD60-2A80ADAF47CAQ38059150-35DD9352-E63D-4CDE-ABE3-0ADA46686AB1Q38193087-9A08F8CE-9EC9-48D4-BCBE-C8B3555F8FAFQ38204053-A4238F1B-16D9-4E92-898C-934093484E48Q38542053-C9B15064-E9C3-44F9-A5C9-8B4F1BCC6593Q38858468-1F0BB37F-8A0C-4590-8D86-D69C48D5280DQ38882974-E8E8685F-3CA2-4D10-8D23-2CDE2171999FQ38978131-8B6555E9-1295-4B10-A9E9-3AD2D05B111A
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Pere-Joan Cardona
@ast
Pere-Joan Cardona
@en
Pere-Joan Cardona
@es
Pere-Joan Cardona
@fr
Pere-Joan Cardona
@nl
Pere-Joan Cardona
@sl
type
label
Pere-Joan Cardona
@ast
Pere-Joan Cardona
@en
Pere-Joan Cardona
@es
Pere-Joan Cardona
@fr
Pere-Joan Cardona
@nl
Pere-Joan Cardona
@sl
prefLabel
Pere-Joan Cardona
@ast
Pere-Joan Cardona
@en
Pere-Joan Cardona
@es
Pere-Joan Cardona
@fr
Pere-Joan Cardona
@nl
Pere-Joan Cardona
@sl
P214
P1053
A-5258-2011
P106
P21
P214
P31
P3835
pere-joan-cardona2
P496
0000-0001-5623-7873
P734
P735
P7859
viaf-315214909